Related Experiment Video

Updated: Sep 24, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

An overview of CDK3 in cancer: clinical significance and pharmacological implications

Theodosia Teo1, Sara Kasirzadeh1, Hugo Albrecht1

  • 1Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.

Pharmacological Research
|May 9, 2022
PubMed

Insights

Cyclin-dependent kinase 3 (CDK3) drives cell cycle progression and cancer. Targeting CDK3 offers therapeutic potential for cancer treatment, despite challenges in developing selective inhibitors.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Cyclin-dependent kinase 3 (CDK3) regulates cell cycle transitions, including G0/G1, preceding other CDK/cyclin complexes.
  • CDK3 influences transcription factors involved in proliferation and differentiation via pathways like EGFR/Ras.
  • CDK3 is upregulated in many cancers but underexpressed in normal tissues, suggesting a role in oncogenesis.

Purpose of the Study:

  • To provide a comprehensive overview of Cyclin-dependent kinase 3 (CDK3) and its therapeutic potential in cancer.
  • To discuss the role of CDK3 in cell cycle regulation and cancer development.
  • To highlight the challenges and opportunities in targeting CDK3 for cancer therapy.

Main Methods:

  • Literature review and synthesis of existing research on CDK3.
  • Analysis of CDK3's role in cell cycle phases and signaling pathways.
  • Discussion of pharmacological inhibition strategies for CDK3.

Main Results:

  • CDK3 directly phosphorylates retinoblastoma protein (Rb) and regulates E2F transcription factors.
  • CDK3 interacts with key signaling pathways like EGFR/Ras, impacting cell proliferation and transformation.
  • Upregulation of CDK3 in cancer, contrasted with its low expression in normal tissues, underscores its oncogenic potential.

Conclusions:

  • CDK3 is a promising therapeutic target in oncology due to its critical role in cell cycle control and cancer progression.
  • The development of selective CDK3 inhibitors is crucial for realizing its therapeutic potential.
  • Targeting CDK3 may offer a novel strategy for treating various types of cancer.
Keywords:
AT7519 (PubChem CID: 11338033)BAY1000394 (PubChem CID: 45380979)CYC065 (PubChem CID: 24983461)CancerCell cycleCyclin-dependent kinaseNU6102 (PubChem CID: 4566)PharmacologyPurvalanol A (PubChem CID: 456214)R547 (PubChem CID: 6918852)RO-3306 (PubChem CID: 135400873)SNX9–1 (PubChem ID: 739323)TG02 (PubChem CID: 16739650)Targeted cancer therapyTranscriptiontamoxifen (PubChem CID: 2733526)

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.8K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K